Welcome to my first contribution to Solar Power World, part of a new series of articles looking specifically at U.S. solar ...
Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.
Ahead of his talk at the 7th Annual Allogeneic Cell Therapies Summit, Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale ...
Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
iOrganBio today announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along with institutional investors IndieBio ...
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback